RENATA MARTINUSSI COUTO

Projetos de Pesquisa
Unidades Organizacionais
Cargo

Filtros

20093
Limpar filtros

Configurações

Data final: 2014 × Autor: JOSEFINA DA SILVA SANTOS ×

Resultados de Busca

Agora exibindo 1 - 3 de 3
  • Imagem de Miniatura
    Artigo IPEN-doc 15124
    Comparative pharmacokinetics and biodistribution studies of sup(99m)Tc annexin V produced by different radiolabeling methods
    2009 - SANTOS, JOSEFINA da S.; PUJATTI, PRISCILLA B.; COUTO, RENATA M.; MENGATTI, JAIR; ARAUJO, ELAINE B.
  • Imagem de Miniatura
    Artigo IPEN-doc 15113
    Standardization of methodology to derivatization and radiolabeling of the anti-CD20 monoclonal antibody from bifunctional chelator dota-nhs-ester
    2009 - MASSICANO, ADRIANA V.F.; AKANJI, AKINKUNMI G.; SANTOS, JOSEFINA S.; PUJATTI, PRISCILLA B.; COUTO, RENATA M.; MASSICANO, FELIPE; ARAUJO, ELAINE B.
  • Imagem de Miniatura
    Artigo IPEN-doc 15332
    In vitro in vivo studies in Balb-c and nude mice of a new sup(177)Lu-bombesin analog developed for prostate tumor diagnosis and treatment
    2009 - PUJATTI, PRISCILLA B.; SANTOS, JOSEFINA S.; COUTO, RENATA M.; SUZUKI, MIRIAM F.; MENGATTI, JAIR; ARAUJO, ELAINE B. de
    In this work we describe the radiolabeling with 177Lu and some properties of the novel bombesin analog BBNp6 – DOTA-X-BBN(6-14), where X is a spacer of six aminoacids. Bombesin (BBN) is an analog of human gastrin releasing peptide (GRP) isolated from the skin of the frog Bombina bombina in 1970. Development of radiolabeled BBN derivatives as agents for diagnostic imaging and systemic radiotherapy has increased considerable because of the observation that GRP receptors (GRPr) are over-expressed in a variety of human tumor cells, such as prostate tumor cells. 177Lu-labeled peptides are attractive due to the excellent radiophysical properties and commercial availability of the radiometal. BBNp6 was labeled with high yield after reacting with 92.5 MBq of 177LuCl3 at 90 °C for 30 minutes and this mixture kept stable for more than 96 hours at 4 ºC and 1 hour in human plasma. In vivo studies showed a multicompartimental distribution model with fast blood clearance, mainly performed by renal pathway. In addition, 177Lu-BBNp6 showed high affinity for PC-3 tumor xenografts, but not for pancreas and intestine (GRP positive tissues), suggesting its specificity and usefulness for prostate tumor treatment. Moreover, scintigraphic images showed that this derivative can also be a tool in this tumor diagnosis. So, BBNp6 is a promising radiopharmaceutical for prostate tumor imaging and treatment.